Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole

Criteria

Inclusion Criteria:

• Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion Criteria:

• None